Melanoma Vaccine
Peptide vaccine has minimal benefit in patients with stage IV melanoma
Published in Clinical Trials Week, March 21st, 2005
"Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by T cells could induce regression of melanoma. This approach was tested in 36 patients with stage IV melanoma. The (MHC class I-restricted) peptides were from gp100, MART-1, tyrosinase, and MAGE-3. The gp100 and MART-1 peptides had been modified to increase their immunogenicity," scientists in Australia report.
"In half the patients (groups 3 and 4) the peptides were given in the adjuvant Montanide-ISA-720, and half the patients in both groups were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2005-03-21)
More Articles from Clinical Trials Week
- Enzymology
Matrix metalloproteinase inhibitor MMI270 helps chemotherapy fight metastasis - Hepatic Encephalopathy
Trial results dispute efficacy of standard management strategies - Non-Hodgkin Lymphoma
Yttrium 90 ibritumomab tiuxetan does not impair subsequent treatment - Pneumococcal Vaccine
Molecular epidemiology of pneumococcal colonization investigated - Vaccine Delivery
Biodegradable microparticles developed for vaccine antigen delivery - Acute Intracerebral Hemorrhage
Journal publishes results of acute intracerebral hemorrhage study - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
